Clinical perspectives of cefditoren pivoxil - new oral third generation cephalosporin


Cite item

Full Text

Abstract

The resistance of community flora is growing slowly. Nevertheless, clinical value of actual resistance of the respiratory, skin, soft tissue and urological pathogens is increasing in relation to macrolides, penicillin, quinolones that demands on the introduction of new antibiotics. Cefditoren pivoxil appeared rather recently in the Russian Federation. Results of microbiological and clinical comparative trials showed its high efficiency and safety as an alternative to the applied antibiotics.

About the authors

Vladimir B. Beloborodov

Russian Medical Academy for Postgraduate Education

Email: vb_beloborodov@mail.ru
MD, PhD, DSci., professor, Department of Infectious diseases, Russian Medical Academy for Postgraduate Education 2/1, Barrikadnaya str., Moscow, 123995, Russian Federation

References

  1. Fenoll A., Granizo J.J., Aguilar L. et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J. Clin. Microbiol. 2009; 47(4): 1012-20.
  2. Fenoll A., Aguilar L., Vicioso M.D., Gimenez M.J., Robledo O., Granizo J.J. Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997-2009. BMC Infect. Dis. 2011; 11: 239.
  3. Farrell D.J., Couturier C., Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PRO TEKT Year 5 (2003-2004). Int. J. Antimicrob. Agents. 2008; 31(3): 245-249.
  4. Калиногорская О.С., Беланов С.С., Волкова М.О. и соавт. Резистентность к антибиотикам и серотипы Streptococcus pneumonia выделенных у детей в Санкт-Петербурге в 2010-2013 годах. Антибиотики и химиотер. 2015; 60(1-2): 10-8.
  5. Fogarty Ch.M., Cyganowski M., Palo W.A. et al. A comparison of cefditoren pivoxil and amoxicill W clavulanate in the treatment of community-acquired pneumonia: A Multicenter, Prospective, Randomized, Investigator-Blinded, Parallel-Group Study. Clin. Ther. 2002; 24: 1854-70.
  6. AlvarezSala J.L., Kardos P., Mart@ínezBeltr@án J. et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditorenpivoxil versus cefuroximeaxetil. Antimicrob. Agents Chemother. 2006; 50(5): 1762-7.
  7. Blasi F., Tarsia P., Mantero M. et al. Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Ther. Clin. Risk Manag. 2013; 9: 55-64.
  8. Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359(22): 2355-65.
  9. Chiba S., Ohta H., Abe K. et al. The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis in combined pulmonary fibrosis and emphysema. Pulm. Med. 2012; 2012: 492960.
  10. Arai S., Kurasawa K., Maezawa R. et al. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. Mod. Rheumatol. 2012. [Epub ahead of print.]
  11. Ishikawa N., Hattori N., Yokoyama A., Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir. Invest. 2012; 50(1): 3-13.
  12. Granizo J.J., Gimnez M.J., Barber J. et al. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the Per-pathogen bacteriologic response in infections caused by streptococcus pneumoniae and haemophilus influenzae: A pooled analysis of seven clinical trials. Clin. Ther. 2006; 12(28): 2061-9.
  13. Di Marco F., Braido F., Santus P. et al. The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage. Eur. Rev. Med. Pharmacol. Sci. 2014; 18: 321-32.
  14. Kyriakidou K.G., Rafailidis P., Matthaiou D.K. et al. Short-versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials. Clin. Ther. 2008; 30: 1859-68.
  15. Talan D.A., Stamm W.E., Hooton T.M. et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. J. A. M. A. 2000; 283: 1583-90.
  16. Gupta K., Hooton T.M., Naber K.G. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 2011; 52: 103-20.
  17. National Institute of Health (Internet). Nonthaburi; 2010 (cited 2012 Feb 20). National Antimicrobial Resistance Surveillance Center of Thailand. Available from: http://narst.dmsc.moph.go.th/a8.php.
  18. Ramakrishnan K., Scheid D.C. Diagnosis and management of acute pyelonephritis in adults. Am. Fam. Physician. 2005; 71: 933-42.
  19. Sanchez M., Collvinent B., Miro O. et al. Short term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomized controlled trial. Emerg. Med. J. 2002; 19: 19-22.
  20. Wells W.G., Woods G.L., Jiang Q., Gesser R.M. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J. Antimicrob. Chemother. 2004; 53: 67-74.
  21. Sadaba B., Azanza J.R., Quetglas E.G., Campanero M.A., Honorato J., Coronel P. et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twiceand thrice-daily regimens in healthy volunteers: a phase I study. Rev. Esp. Quimioter. 2007; 20: 51-60.
  22. Cuevas O., Cercenado E., Gimeno M., Marin M., Coronel P., Bouza E. Comparativein vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study. Diagn. Microbiol. Infect. Dis. 2010; 67: 251-60.
  23. Monmaturapoj T., Montakantikul P., Tragulpiankit P. et al. A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400 mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis. Int. J. Infect. Dis. 2012; 16: e843-9.

Copyright (c) 2016 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies